MedPath

Progressive Resistance Exercise in Rheumatoid Arthritis

Phase 4
Completed
Conditions
Rheumatoid Arthritis
Registration Number
NCT02219022
Lead Sponsor
Federal University of São Paulo
Brief Summary

A randomized controlled trial with rheumatoid arthritis patients will be realized. Patients will be randomized into two groups. Experimental group will do a 12 weeks training of progressive resistance exercise for global muscles and remain with the clinical treatment and the control only remain with the clinical treatment. Patients will be evaluated at baseline, after 6, 12 and 24 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Rheumatoid arthritis according to American College of Rheumatology 2010
  • Both genders
  • Age between 18 and 65 years
  • Functional class I, II and III
  • Stable medication within the three months preceding the study
  • Haven't done any kind of regular exercise (two or more times per Week) for at least three months before study start
  • Have agreed to participate in the study and signed an informed consent form.
Exclusion Criteria
  • Participating in another type of study
  • Have difficulty understanding the evaluation tools with fibromyalgia
  • Joint deformities that make impossible do the exercises
  • Other musculoskeletal diseases
  • Other diseases that contraindicate exercises.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in pain - Visual analogue scalebaseline, 6, 12 and 24 weeks
Secondary Outcome Measures
NameTimeMethod
Change in quality of life - Short form 36baseline, after 6, 12 and 24 weeks
Change in strength - 1 maximum repetitionbaseline, after 6, 12 and 24 weeks
Change in function capacity - Health Assessment questionaireBaseline, after 6, 12 and 24 weeks

Trial Locations

Locations (1)

Universidade Federal de Sao Paulo

🇧🇷

Sao Paulo, SP, Brazil

Universidade Federal de Sao Paulo
🇧🇷Sao Paulo, SP, Brazil

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.